Overview

This trial is active, not recruiting.

Condition diabetes
Sponsor Assistance Publique - Hôpitaux de Paris
Start date December 2012
End date December 2016
Trial size 17 participants
Trial identifier NCT02072551, GLUCONEO

Summary

The main objective of this study is to evaluate Beta cells in patients with a neonotal diabetes linked to a genetic abnormality Metabolic caracteristics will described using a transversal cohort study.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective
Arm
Adult with neonatal diabetes (before 1 year ) and need for insulin

Primary Outcomes

Measure
Mean insulin secretion output
time frame: Week after inclusion

Secondary Outcomes

Measure
insulin secretion outout after arginine perfusion
time frame: during hospitalisation (3 days)
sensitivity to insulin
time frame: during hospitalisation (3 days)
glucago secretion output
time frame: during hospitalisation (3 days)

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Age : 18 à 65 year - diabetic patient with a neonatal diabetis (before 1 year old) and need for insuline or patient with a relative having neonatal diabetis Exclusion Criteria: Diabète induit (médicaments - ex corticoïdes) ou syndromique - infection - cancer - pegnancy

Additional Information

Official title Devenir au Long Cours de la Cellule bêta Chez Les Adultes Porteurs d'Anomalies génétiques à l'Origine du Diabète Néonatal
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris.